efficacy and safety of elranatamab bcma-cd3 bispecific antibody, in patients with rrmm
Published 3 years ago • 1K plays • Length 7:06
Download video MP4
Download video MP3
Similar videos
-
7:25
updated phase 1 results of teclistamab, a bcma × cd3 bispecific antibody, in rrmm
-
9:14
efficacy and safety of elranatamab in pts with relapsed/refractory multiple myeloma: magnetismm-3
-
7:04
safety and efficacy of elranatamab in rrmm & prior bcma therapies: analysis from magnetismm studies
-
9:57
teclistamab, a bcma × cd3 bispecific antibody, in pts with rrmm: updated phase 1 results
-
6:54
elranatamab: extended follow-up & biweekly admin for rrmm | magnetismm-3 study | asco 2023
-
8:33
initial safety results for phase 2 magnetismm-3 trial presented at asco 2022
-
4:17
evaluating the safety and efficacy of elranatamab in multiple myeloma
-
4:28
first-in-human study of tnb-383b, a bcma x cd3 bispecific t-cell redirecting antibody, in pts w/rrmm
-
7:26
regn5458, a bcmaxcd3 bispecific monoclonal antibody, in a phase 1/2 1st-in-human study in rrmm pts
-
9:41
redirectt-1 study: dual targeting of bcma and gprc5d in rrmm pts with teclistamab and talquetamab
-
11:22
updated efficacy/safety results of majestec-1 (teclistamab) at asco 2022
-
3:20
phase i trial of a bcma-cd3 bispecific antibody in r/r myeloma
-
9:07
elranatamab in combination with daratumumab for pts with rrmm: phase 3 magnetismm-5
-
1:15
safety & efficacy of bispecific antibodies in multiple myeloma: teclistamab & elranatamb
-
1:52
impact of prior bcma-directed therapy on the efficacy of elranatamab in r/r multiple myeloma
-
3:30
sc vs. iv administration of a bcma-cd3 bispecific antibody for r/r myeloma
-
7:44
ash23: abbv-383 bcma x cd3 bispecific antibody for relapsed/refractory myeloma | ravi vij, md, mba
-
7:18
response rate on phase 1/2 trial regn5458 (bcmaxcd3 bispecific antibody) for rrmm patients
-
3:44
phase i study of teclistamab, a humanized bcma x cd3 bispecific antibody, in relapsed/refractory mm
Clip.africa.com - Privacy-policy